key: cord-0035143-u8an6opj
authors: Cui, Lunbiao; Stratton, Charles W.; Tang, Yi-Wei
title: Diagnosis and Assessment of Microbial Infections with Host and Microbial microRNA Profiles
date: 2012-04-05
journal: Advanced Techniques in Diagnostic Microbiology
DOI: 10.1007/978-1-4614-3970-7_46
sha: 40d77d649b770d90109d0180f9e95223b8a3289f
doc_id: 35143
cord_uid: u8an6opj

Biomarkers are continuously being sought in the field of diagnostic microbiology for the laboratory diagnosis and assessment of microbial infections. A set of clinical and laboratory criteria necessary for an ideal diagnostic marker of infection have previously been proposed by Ng and his colleagues [1]. According these criteria, an ideal biomarker should possess at a minimum the following characteristics: (a) biochemically, a biomarker should be stable and remain significantly deregulated in the body fluid compartment for at least 12–24 h even after commencement of appropriate treatment that may allow an adequate time window for specimen collection or storage without significant decomposition of the active compound until laboratory processing; (b) its concentration should be determined quantitatively and the method of measurement should be automatic, rapid, easy, and inexpensive; (c) the collection of a specimen should be minimally invasive and require a small volume (e.g., <0.5 mL blood). Numerous biomarkers have been found and tested in clinical practice. Currently, microRNA (miRNA) molecules are without a doubt the biomarkers with the greatest potential capacities in the diagnostic microbiology field.

Biomarkers are continuously being sought in the fi eld of diagnostic microbiology for the laboratory diagnosis and assessment of microbial infections. A set of clinical and laboratory criteria necessary for an ideal diagnostic marker of infection have previously been proposed by Ng and his colleagues [ 1 ] . According these criteria, an ideal biomarker should possess at a minimum the following characteristics: (a) biochemically, a biomarker should be stable and remain signi fi cantly deregulated in the body fl uid compartment for at least 12-24 h even after commencement of appropriate treatment that may allow an adequate time window for specimen collection or storage without signi fi cant decomposition of the active compound until laboratory processing; (b) its concentration should be determined quantitatively and the method of measurement should be automatic, rapid, easy, and inexpensive; (c) the collection of a specimen should be minimally invasive and require a small volume (e.g., <0.5 mL blood). Numerous biomarkers have been found and tested in clinical practice. Currently, microRNA (miRNA) molecules are without a doubt the biomarkers with the greatest potential capacities in the diagnostic microbiology fi eld.

The fi rst miRNA, lin-4, was inadvertently discovered in Caenorhabditis elegans in 1993 by Lee and colleagues [ 2 ] . However, recognition of the miRNA let-7 and its ability to regulate lin-14 by Ruvkun and colleagues [ 3 ] in 2000 resulted in the establishment of this new class of regulatory nucleic acids and their potential value in diagnostic microbiology.

The majority of the characterized miRNA is intergenic and is located in introns. Primary miRNA transcripts, i.e., pri-miRNAs, are transcribed by RNA polymera-seII or III. In the nucleus, ribonuclease Drosha cleaves pri-miRNAs and releases 60-80-nt stem-loop intermediate structures named pre-miRNAs. The pre-miRNAs are transported to cytoplasm by exportin-5 protein, and then are cleaved by Dicer RNase III to form a mature double-stranded miRNA. One strand of the miRNA duplex is subsequently unwound and then incorporated into an effector protein complex termed RNA-induced silencing complex (RISC), which is responsible for the gene silencing in a posttranscriptional manner [4] [5] [6] . Mature miRNAs are single-stranded RNA molecules of about 19-25 nucleotides in length. Through partial homology to the 3 ¢ -untranscribed region (UTR) in target mRNAs, miRNAs control of gene expression via repression of translation as well as reducing mRNA levels directly.

A large number of miRNAs have been found in various animal and plant tissues. According to miRBase 18.0 ( http://microrna.sanger.org/ ), which is a collective registry of currently known miRNA sequences and targets hosted by the Sanger Institute, there are currently 1,527 recognized miRNA sequences in the Homo sapiens genome; this number is constantly growing as new miRNA sequences are discovered. Recently, virus-encoded miRNAs have been discovered; these miRNAs may function as controls for viral replication and thus limit antiviral responses, inhibit apoptosis, and stimulate cellular growth [ 7 ] . Moreover, unique host cell miRNAs expression pro fi les have been revealed in response to various microbial infections [ 8, 9 ] . Host miRNA appears to play a role in viral replication and may be used by host cells to control viral infection.

Beginning in 2008, miRNAs have been found circulating in serum and plasma as well as other body fl uids such as saliva, tears, and urine. Some of these miRNAs appear to be enriched in speci fi c fl uids [ 10, 11 ] . These circulating miRNAs subsequently have become the focus of ongoing research. The properties, origin, function, and relationship with disease of circulating miRNAs have been intensively explored. A number of important observations have been noted. Circulating miR-NAs are present in a stable form that is protected from endogenous RNase activity [ 12, 13 ] . Some groups also reported a higher stability of miRNAs compared to mRNA in samples obtained from formalin-fi xed paraf fi n-embedded tissues [14] [15] [16] . The expression level of miRNAs has been noted as consistent among individuals of the same species [ 12 ] . Expression alteration of circulating miRNAs has been reported to be associated with pathophysiological states including various cancers, heart disease, pregnancy, and diabetes [ 17, 18 ] . Needless to say, serum, plasma, and other body fl uid specimens are generally available for clinical testing. Pro fi ling hundreds of miRNA requires only 200 m L sera [ 13 ] . Thus, these unique and stable characteristics of circulating miRNAs potentially make them extremely useful biomarkers for disease diagnosis and prognosis.

The fi rst virus-encoded miRNA was described by Pfeffer and his colleagues in 2004 when they identi fi ed fi ve Epstein-Barr virus (EBV)-encoded pre-miRNAs [ 19 ] . Since then, hundreds of virus-encoded miRNAs have been described in humans, animals, and plants. Examples of human virus-encoded miRNA are shown in Table 46 .1 . Bewilderingly, more than 95 % of the virus-encoded miRNAs known today are of herpesvirus origin. Moreover, almost all virus-encoded miRNAs are encoded by DNA viruses except those encoded by retroviruses (HIV-1), which reverse-transcribe and integrate their genetic material into host DNA. Aberrantly expressed circulating miRNAs have been explored for the diagnosis and prognosis of several infectious diseases, including sepsis [ 20, 21 ] , HBV [ 22 ] , and HCV [ 23 ] .

Viral miRNAs target perfectly complementary viral mRNAs as well as imperfectly complementary viral and/or cellular mRNAs. Viral miRNAs modulate expression of host gene involved in cell proliferation and survival, stress responses, and antiviral defense pathways, which are pivotal for viral replication. Another primary function of virus miRNAs is to regulate the latent-lytic switch. During latency, the host cell [ 24 ] . There is an accumulating amount of evidence that has demonstrated that virus-encoded miRNAs mediate evolutionarily conserved functions (e.g., immune evasion, cell cycle control, and promotion of latency, etc.). The miRNAs themselves show poorly primary sequence conservation [ 25 ] . These phenomena raise an important question: can viral miRNAs be used as the detection maker for virus infection during the latent infection phase despite the fact that little or no viral protein is being produced? Further studies are needed to evaluate this hypothesis.

Microbial infections are known to downmodulate at least some cellular mRNAs and thereby exert physiological effects. Microbial infections induce changes in the host miRNA expression pro fi le, which may also have a profound effect on the outcome of infection. Host miRNA may directly or indirectly affect virus replication and pathogenesis. For example, liver-speci fi c miR-122 is required for HCV replication [ 26, 27 ] . Moreover, miR-28, miR-125b, miR-150, miR-223, and miR-382 are overexpressed in resting CD4+ T lymphocytes compared to their activated counterparts. These miRNAs are able to target sequences near the 3 ¢ portion of HIV-1 mRNA. This fi nding suggests that miRNAs may contribute to viral latency [ 28 ] . However, it is unclear whether these miRNAs are actively inhibited by viral factors or whether their deregulation is due to host responses. Host miRNA expression pro fi les have been noted to represent speci fi c pathophysiological states [ 17, 18 ] . Theoretically, a characteristic pro fi le should be potential biomarkers for disease diagnosis and prognosis. A number of studies have been conducted to demonstrate this theory and promising results have been seen in a number of altered physiological states including various cancers, heart disease, pregnancy, diabetes, injury, and infection. The use of these miRNA pro fi les in infection diseases is discussed in next section.

Houzet and colleagues have pro fi led miRNAs in peripheral blood mononuclear cells (PBMCs) from HIV-1 infected patients. They found the T cell abundant miR-NAs (miR-223, miR-150, miR-146, miR-16, and miR-191) were downregulated three-to ninefold compared to cells from uninfected controls, depending on the disease stage of the patient [ 29 ] . Triloubet et al. reported increased expression of 11 miRNAs including miR-122, miR-370, miR-373*, and miR-297 in HIV-1 infected Jurkat cells, whereas expression of the polycistronic miRNA cluster miR17/92 (comprises miR-17-(5p/3p), miR-18, miR-19a, miR-20a, miR-19b-1, and miR-92-1) was strongly decreased [ 30 ] . Like HIV-1, human T cell leukemia virus type 1 (HTLV-1) also infects CD4+ T cells. Two miRNA-pro fi ling studies have been performed in infected cell lines and ATL (adult T-cell leukemia) cells [ 31, 32 ] . The studies fi nd two common miRNAs that are consistently downregulated in the context of HTLV-1 infection.

The miRNA expression pro fi le in bronchoalveolar stem cells (BASCs) infected with SARS coronavirus (CoV) has been determined using miRNA microarray [ 33 ] . A total of 116 miRNAs were found differentially expressed. Upregulated BASC miRNAs-17*, -574-5p, and -214 are co-opted by SARS-CoV to suppress its own replication and evade immune elimination until successful transmission takes place. In contrast, viral nucleocapsid and spike protein targets seem to co-opt downregulated miR-223 and miR-98 respectively. Differentially expressed miRNAs in chicken lung and trachea infected with a low pathogenic strain of H5N3 avian in fl uenza virus were analyzed by a deep sequencing approach [ 34 ] . A total of 73 and 36 miRNAs are differentially expressed in lungs and trachea upon virus infection, respectively. Lung cellular "microRNAome" of mice infected by reconstructed 1918 in fl uenza virus was compared with that of mice infected by a nonlethal seasonal in fl uenza virus, A/Texas/36/91. A group of microRNAs, including miR-200a and miR-223, was differentially expressed in response to in fl uenza virus infection and infection by these two in fl uenza viruses induced distinct microRNA expression pro fi les [ 35 ] .

We have previously analyzed the miRNA expression pro fi les from adenovirus type 3 (AD3) infected human laryngeal epithelial (Hep2) cells using a SOLiD deep sequencing. A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than in control cells [ 36 ] .

Wang et al. monitored the time course of cellular miRNA expression in human cytomegalovirus (CMV) infected cells using miRNA microarrays. Forty-nine miRNAs signi fi cantly changed on at least one time point [ 37 ] . There were no global unidirectional changes, with changes for these miRNAs sometimes being transient. The miR-199a/214 cluster (miR-199a-5p, miR-199a-3p, and miR-214) has recently been found to be downregulated in CMV-infected cells [ 38 ] .

Infection of human primary neural cells with a high phenotypic reactivator herpes simplex viruses-1 (HSV-1) (17syn+) can induce upregulation of a brain-enriched microRNA (miRNA)-146a [ 39 ] . Both miR-101 and miR-132 are also found to be highly upregulated after HSV-1 [ 40, 41 ] . Kaposi's sarcoma (KS) associated herpesvirus (KSHV) is the etiological agent of KS. The M type K15 protein of KSHV induces the expression of microRNAs miR-21 and miR-31 via this conserved motif [ 42 ] , while K13 strongly stimulated upregulation of miR-146a [ 43 ] .

EBV is an oncogenic herpes virus that is endemic in humans and also can be found in about 15 % of patients with diffuse large B-cell lymphoma (DLBCL). EBV de novo infection of primary cultured human B-cells results in a dramatic downregulation of cellular miRNA expression, with 99.5 % of the miRNAs detected being downregulated, with an average downregulation of 19.92-fold [ 44 ] . Imig et al. found that expression of hsa-miR-424, -223, -199a-3p, -199a-5p, -27b, -378, -26b, -23a, -23b were upregulated and those of hsa-miR-155, -20b, -221, -151-3p, -222, -29b/c, -106a were downregulated more than twofold due to EBV-infection of DLBCL [ 45 ] . Cameron et al. demonstrated differential expression of cellular miRNAs in type III versus type I EBV latency including elevated expression of miR-21, miR-23a, miR-24, miR-27a, miR-34a, miR-146a and b, and miR-155. In contrast, miR-28 expression was found to be lower in type III latency [ 46 ] .

In vitro infection assays have revealed that Helicobacter pylori infection can affect miRNA expression pro fi les: speci fi cally, miRNAs such as miRNA-155, miRNA-16, and miRNA-146a are signi fi cantly upregulated in human gastric epithelial cells during infection [ 47 ] . More recently, expression patterns of miRNA in gastric mucosa infected with H. pylori using endoscopic biopsy specimens have been determined by microarray. There were 31 differentially expressed miRNAs between the H. pylori -infected and -uninfected mucosa (more than twofold) and miRNA expression pro fi ling could distinguish H. pylori status, with the eight miRNAs yielding acceptable sensitivity and speci fi city [ 48 ] . Muscle-speci fi c miRNAs miR-1 and miR-133 were signi fi cantly downregulated in the stomachs after long-term infection with H. pylori in mouse model [ 49 ] . Schulte et al. identi fi ed differentially regulated miRNAs by comparative deep sequencing of a total of 14 cDNA libraries prepared from the small RNA population of host cells before or after Salmonella infection, or in mock-treated cells. In murine RAW 264.7 cells, upregulation of miR-21, miR-146a/b, and miR-155 was observed after infection, they also observed signi fi cant downregulation of several let-7 family members, namely, let-7a/c/d/f/g/i, and miR-98. In HeLa cells, a signi fi cant upregulation of miRNAs by Salmonella was limited to miR-1308. In contrast, miR-21, miR-146a/b, or miR-155 remained unaffected. Intriguingly, downregulation of let-7 miRNAs also occurred in HeLa cells [ 50 ] .

Sharbati et al. performed miRNA as well as mRNA expression analysis of human monocyte-derived macrophages infected with several Mycobacterium avium hominissuis strains using microarrays as well as qRT-PCR. They found that the expression of let-7e, miR-29a, and miR-886-5p were increased in response to mycobacterial infection at 48 h [ 51 ] . Expression of miR-23b, miR-34a, and miR-218 are signi fi cantly reduced by human papillomavirus (HPV) E6 infection, while HPV E7 infection downregulates expression of miR-15a/miR-16-1 and miR-203 [ 52 ] .

Accurate determination of miRNAs expression levels in a speci fi c cell, tissue, or fl uids is prerequisite to assess their biological, pathological, and clinical roles in health and disease. Theoretically, all mRNA detection methods should be useful for miRNA analysis. However, the following characteristics of miRNA sequences make quanti fi cation of miRNAs expression a technical challenge. First, mature miRNA are short (only 19-25 nucleotides; nts) and miRNAs within the same family may differ by a single nucleotide, which makes it dif fi cult to design speci fi c primers and probes and to reliably amplify or label each miRNA without introducing signal bias. Second, miRNAs are heterogeneous in their GC content, which results in melting temperatures (Tm) of these nucleic acid duplexes that vary widely. Finally, the target sequence is present in the primary miRNA transcript (pri-miRNA), the precursor miRNA (pre-miRNA), and the mature miRNA. It is therefore important to ensure that the nonactive pri-miRNA and pre-miRNA precursor species do not contribute to the detection signal [ 53 ] . Several standard methods for quanti fi cation of mRNA levels have been successfully adapted to miRNA including northern blotting, cloning, in situ hybridization, RT-PCR, and microarrays. In addition, emerging techniques based on colorimetric, fl uorescence, bioluminescence, enzyme, and electrochemical, hold immense promise for the future of miRNA detection. However, technical issues must be addressed before they are accepted among the current standard methods [ 54 ] .

Northern blotting was the fi rst technique used to detect miRNAs and is considered the "gold standard" for characterizing miRNA expression. The basic procedures of miRNA northern blotting are similar to traditional blotting and are done as follows: (a) the small RNA molecules are separated by using high percentage denaturing urea-acrylamide gels rather than the usual agarose electrophoresis gels; (b) the small RNA molecules are transferred from the gel onto a membrane; (c) the miRNA molecules are fi xed on the membrane through various cross-linking procedures; (d) the membrane is hybridized with radiolabeled oligonucleotide probes. Northern blotting methods are able to determine the absolute amount of miRNA in a sample by blotting a dilution series of synthetic oligo miRNA molecules of known concentrations in parallel with the sample. The concentration of miRNA in the sample can be calculated by a standard curve obtained from the dilution series. However, short length as well as low prevalence of mature miRNA molecules can lead to poor sensitivity of such routine northern analysis. It requires a large amount of total RNA for each sample (generally, more than 5 m g). Other disadvantages of this method include low throughput and potential environment hazards of radiolabeling. Several technical modi fi cations have been used to improve detection sensitivity. LNA (locked nucleic acid)-modi fi ed oligonucleotide probes increases the af fi nity between LNA probes and target miRNA which results at least tenfold increase of sensitivity [ 55 ] . Using soluble carbodiimide cross-linking method increases the ef fi ciency of miRNA that are fi xed on the membrane, which can increase by 25-50-fold miRNA detection sensitivity compared to the traditional UV cross-linking method [ 56 ] .

The most widely used method for detection and quali fi cation of miRNA appears to be real-time quantitative RT-PCR (qRT-PCR). The small size of the mature miRNA sequences as well as sequence homology between the mature and precursor miRNA forms limits the direct application of conventional RT-PCR protocols to miRNA detection. To solve these problems, innovative solutions have been applied for each step of qRT-PCR used for the quantitative analysis of miRNAs. The fi rst step in qRT-PCR of miRNAs is the accurate and complete conversion of miRNA into cDNA. Two different approaches for reverse transcription of miRNAs have been reported. In the fi rst approach, miRNAs are reverse transcribed individually by using miRNAs-speci fi c reverse transcription primers. Both stem-loop (Applied Biosystems Co, Fig. 46 .1a ) and a linear primer (Exiqon, Fig. 46 .1b ) containing partial complementary sequence of 3 ¢ -end of miRNA can be annealed to miRNA in order to prime the reverse transcription. The double stranded structure of the stem-loop primer prevents its nonspeci fi c binding to pre-and pri-miRNAs, thereby increasing the speci fi city of the assay. Unlike stem-loop primer, the design of the linear primer is simpler. But the linear primer cannot discriminate mature miRNA from their precursors.

Another approach is done as follows: miRNAs are fi rst tailed with adenosine nucleotides at 3 ¢ -end of miRNA with Poly(A) Polymerase (Fig. 46 .1c ) or linker adaptor with T4 RNA Ligase 1 (Fig. 46.1d ) . Then, a primer consisting of an oligo(dT) sequence with a universal primer-binding sequence at its 5 ¢ -end or a universal primer complementary to the 3 ¢ -end of the linker is used to prime reverse transcription [ 53 ] . The universal reverse primer sequence is introduced into the cDNA during reverse transcription. The design of the miRNA speci fi c forward primer is critical for the speci fi city and sensitivity of the qRT-PCR assay. LNA modi fi cation is a widely used method for increasing the Tm and the speci fi city of primer. Each incorporated LNA monomer increases the Tm up to 2-8 °C, depending upon the position of the LNA moiety in the oligonucleotide primer [ 57 ] .

There are two approaches available for detection of qRT-PCR products. One approach uses SYBR Green dye whose fl uorescence increases approximately 100times upon intercalating into dsDNA chain; this property is used to monitor real time ampli fi cation products as they accumulate during the PCR reaction. One limitation of the SYBR Green-based method is that target PCR products and nonspeci fi c products cannot be discriminated. Therefore, a melting point analysis usually required following the PCR ampli fi cation, which can be reached by using a duallabeled hydrolysis TaqMan probe. The basis for this type of TaqMan probe detection has been reviewed by Benes and Castoldi [ 53 ] . The characteristics of TaqMan miRNA assays make them ideally suited for detection of mature miRNAs. Moreover, these TaqMan miRNA assays can discriminate related miRNAs that differ in only 1 ( d ) . Then, a primer consisting of an oligo(dT) sequence with a universal primer-binding sequence at its 5 ¢ -end ( c ) or a universal primer complementary to the 3 ¢ -end of the linker ( d ) was used to prime reverse transcription one nucleotide. However, the cost of the TaqMan probes is higher than the SYBR Green method, which limits its routine use in most laboratories.

The qRT-PCR method has demonstrated a high sensitivity and speci fi city with ability to accurately detect miRNAs in a single stem cell [ 58, 59 ] . Only low amounts of starting material (in the range of nanograms of total RNA) are needed and quantitative results can be acquired within 3 h. This method also has a considerably larger dynamic range compared to microarray analysis. Recently, the qRT-PCR technique has been adapted for increased throughput by developing a miRNA PCR array that can detect hundreds of miRNAs at one reaction tube. Examples include the TaqMan Low density microRNA Array (TLDA, Applied Biosystems) and the RT² miRNA PCR Arrays (SABioscience, a Qiagen Company).

Another widely used high-throughput technique for analysis of the expression level of miRNA molecules is microarray technology. The microarray technology was fi rstly applied to miRNA studies in 2003 [ 60 ] . Since then, numerous approaches based on different microarray platforms have been developed for miRNA quanti fi cation. The basic procedures of miRNA quanti fi cation using a microArray platform including (a) miRNA probe design and array preparation, (b) isolation of miRNA and labeling, (c) hybridization and signal detection. A schematic fl ow chart of the miRNA pro fi ling microarray is shown in Fig. 46. 2 . The design of the microRNA probes, isolation of microRNA from samples and the labeling of miRNAs are the most critical procedures in the miRNA microarray assay. The short length of miRNAs makes design of the probes more dif fi cult because the design of the probe is almost exclusively determined by sequence of the miRNA itself. Sequence of the miRNA determines the wider Tm distribution of the probes. Therefore, Tm normalization of the full set of probes is absolutely required since the hybridization is usually carried out at one temperature. To solve this problem, two techniques, LNA utilization or adjusting the lengths of the probes, have been successfully used to normalize Tm value [ 61, 62 ] . Quantity of miRNA is also very important for miRNA microarray assay, since the abundance of miRNAs in total RNA is very low and a relatively large amount of miRNA is needed in comparison to a RT-PCR assay. Conventional denaturing urea-acrylamide gel electrophoresis combined with a commercialized kit (e.g., the mirVana™ microRNA isolation kit of Ambion, Inc. and the PureLink™ microRNA isolation kit of Invitrogen Co) have demonstrated excellent ef fi ciency in isolating miRNA.

Labeling of miRNA is an absolutely key step for the overall sensitivity of the microarray. Many methods have been developed to label miRNA, and these can be classi fi ed into two main categories: direct labeling and indirect labeling. Direct labeling with fl uorescent dye can be accomplished enzymatically. Currently used methods including labeling through poly(A) polymerase, labeling though T4 RNA ligase, guanine labeling, and labeling microRNA through a RNA-primed arraybased Klenow enzyme assay (RAKE). Fluorescent dye also can conjugate with adjacent 3 ¢ -OH of mature miRNAs using a chemical reagent [ 63, 64 ] . Indirect labeling methods including labeling through miRNA reverse transcript, the RT-PCR product of miRNA or the in vitro transcript of miRNA. The advantages of indirect labeling are obvious, since the reverse transcription product of miRNAs are more stable and easy to preserve. In addition, miRNA can be ampli fi ed and labeled synchronously through PCR or in vitro transcription, which is very useful for lowabundance miRNAs. Although direct labeling is simple, this method has inherent problems including the fact that guanine labeling is not suitable for miRNAs lacking G residues, that T4 ligase labeling can introduce base bias, and that the procedure of chemical labeling is somewhat complicated. Though indirect labeling is more sensitive, this method may introduce arti fi cial errors during the ligation and PCR ampli fi cation procedures.

Another microarray technique, which uses biotin labeled miRNAs to hybridize with LAN probes, has been coupled to xMAP suspension microspheres (Luminex Co) to offer more rapid and reproducible results than does solid planar array due to its favorable reaction kinetics in liquid phase. Using this technique, a single nt difference can be discriminated [ 65 ] . Microarray technology has proven to be standard technique for pro fi ling miRNA expression.

Next-generation sequencing (NGS) is also called massively parallel or deep sequencing and is becoming the most effective method for miRNA analysis. Sequence throughput of NGS is unapproachable by other miRNA analysis techniques, since they lay DNA fragments on a single chip and simultaneous sequencing up to millions of these fragments in parallel. The principle of NGS has been described in other chapter of this book and elsewhere [ 66, 67 ] . Currently, three main platforms are in widespread use for miRNA pro fi ling and discovery: the Roche (454) GS FLX sequencer, the Illumina Genome Analyzer and the Applied Biosystems SOLiD sequencer. The methodologies of the NGS for miRNA analysis are similar and include sRNA isolation, library preparation, sequencing, and data analysis. In addition to increased throughput, NGS technique signi fi cantly reduce cloning biases observed with traditional capillary sequencing since sequence reads are generated from fragment libraries that do not need to be cloned and ampli fi ed.

Another key advantage of NGS over microArrays in miRNA study is that it can pro fi le unknown genes since no sequence speci fi c probes are needed for detection. Currently, most novel miRNAs have been discovered and characterized through NGS. NGS can also gauge miRNA expression level by counting clone frequencies, which has demonstrated more sensitivity than microArrays [ 66 ] . One disadvantage of NGS to comprehensively pro fi le mRNA expression is that this technique is rather expensive compared to microArray though its cost has signi fi cantly decreased with the development of commercial platforms. Another limitation of NGS is that the read length is relatively short (35-500 bp) compared to traditional capillary sequencing (1,000-1,200 bp). This limits their use for de novo assembly of complete genomes but makes them become the ideal instruments for miRNA pro fi ling since the length of miRNAs (21-35 nucleotides) is shorter than the read length of NGS.

As described above, each technique for miRNA detection has its advantages and disadvantages. The method used should best fi t the research goal and experimental conditions. For example, for new miRNA discovery and identi fi cation, in addition to sequencing technique, cloning of miRNA may be the simplest method. In situ hybridization is more suitable for location of miRNA in tissue. Northern blotting is very sensitive, but it is very time-consuming and not practical in large clinical studies for routine detection of the expression of hundreds of miRNAs. qRT-PCR is able to detect low copy numbers with high sensitivity and speci fi city. When studying the expression levels of multi-miRNAs simultaneously, microarray and sequencing may be the best choice. Another important problem is that although each platform is relatively stable in terms of its own microRNA pro fi ling intrareproducibility, the interplatform reproducibility among different platforms is low [ 68 ] . An "industry standard" for analysis of miRNA expression awaits further advances in both technology and computation [ 69 ] .

Although altered miRNA expression pro fi les have been detected in various tissues or cells following microbial infection, these pro fi les have not yet been used as biomarkers in clinical practice because obtaining infected tissues and cells is dif fi cult without invasive procedures. As described above, circulating miRNAs in serum/plasma seem more suitable for biomarkers that can be easily used for the diagnosis or prognosis of these infections. Some potential uses are discussed in the next section.

Diagnosis and monitoring of sepsis can be dif fi cult because many of its signs and symptoms can be caused by other noninfectious disorders. The current gold standard for diagnosing septicemia is the blood culture, which generally takes several days or longer. Other early biomarkers of sepsis are being investigated; these include acute phase proteins (C-reactive protein), cytokines (IL-1, -6, -10 and TNF-a), chemokines (IL-8, MCP-1, and G-CSF), procalcitonin, and metabonomic. To date, these biomarkers have not demonstrated suf fi cient sensitivity and/or speci fi city to guide clinical management. Host miRNA expression pro fi les have been intensively studied using both in vitro or in vivo models of in fl ammation that are triggered by Escherichia coli lipopolysaccharide (LPS) stimulation. For example, expression of miR-146, miR-155, and miR-132 increased in human acute monocytic leukemia cell line THP-1 in response to LPS stimulation [ 70 ] . Upregulation of miR-155, miR-223, miR-146a and downregulation of miR-125b, miR-144, and miR-142-5p have been observed in human monocyte-derived dendritic cells by Ceppi et al. [ 71 ] . Schmidt et al. screened for differentially expressed miRNAs in circulating leukocytes using an in vivo model of acute in fl ammation also triggered by LPS [ 72 ] . They found four miRNAs were downregulated (miR-146b, miR-150, miR-342, and let-7g) and one was upregulated (miR-143).

Vasilescu et al. pro fi led genome-wide miRNAs by microarray in peripheral blood leukocytes of sepsis patients and found that miR-150, miR-182, miR-342-5p, and miR-486 expression pro fi les differentiated sepsis patients from healthy controls [ 20 ] . Moreover, miR-150 levels were signi fi cantly reduced in plasma samples of sepsis patients and correlated with the level of disease severity. Finally, these investigators noted that the plasma levels ratio for miR-150/interleukin-18 can be used for assessing the severity of the sepsis. More recently, Wang et al. have analyzed seven miRNAs expression levels in patients diagnosed with sepsis, systemic in fl ammatory response syndrome (SIRS), and healthy controls using a qRT-PCR assay [ 21 ] . They determined serum miR-146a and miR-223 were signi fi cantly reduced in septic patients compared with SIRS patients and healthy controls. The areas under the receiver operating characteristic curve of miR-146a, miR-223, and IL-6 were 0.858, 0.804, and 0.785, respectively.

HBV infection is also known to modulate the expression of host cellular miRNAs, which then participate in development of HBV-related liver diseases. The miRNA pro fi les in chronic hepatitis B patient tissues or in HBV-expressing cells are reviewed by Liu et al. [ 73 ] . Li et al. pro fi led serum miRNAs of healthy controls, HBV-, HCV-, and HBV-positive hepatocellular carcinoma (HCC)-affected individuals by Solexa sequencing followed by validation with quantitative RT-PCR assay [ 21 ] . These investigators successfully identi fi ed 13 miRNAs that are differentially expressed in HBV serum. This 13-miRNA-based biomarker accurately discriminated not only HBV cases from controls and HCV cases, but also HBV-positive HCC cases from control and HBV cases. For example, when using four markers (miR-375, miR-10a, miR-223, and miR-423) to separate the control and HBV groups, the AUC was 99.9 ± 0.1 % (sensitivity: 99.3 %; speci fi city: 98.8 %). Similarly, two markers (miR-92a and miR-423) could separate the control and HCV groups with a high speci fi city and sensitivity (AUC: 99.6 ± 0.4 %; sensitivity: 97.9 %; speci fi city: 99.4 %). The control and HBV-positive HCC group could be clearly separated by 5 markers (miR-23b, miR-423, miR-375, miR-23a, and miR-342-3p; AUC: 99.9 ± 0.1 %; sensitivity: 96.9 %; speci fi city: 99.4 %). Similarly, the HBV and the HBV-positive HCC group could be separated by two markers (miR-10a and miR-125b; AUC: 99.2 ± 0.6 %; sensitivity: 98.5 %; speci fi city: 98.5 %).

Another study pro fi led miRNA expression on pooled sera obtained from identi fi ed groups of chronic asymptomatic carriers (ASC), patients with chronic hepatitis B (CHB) and HBV-associated acute-on-chronic liver failure (ACLF), as well as healthy controls (HC) using Applied Biosystems TaqmanArray assay [ 74 ] . A total of 37 miRNAs were ampli fi ed from HC, whereas 77, 101, and 135 were ampli fi ed from ASC, CHB, and ACLF, respectively. The expression levels of most miRNAs were also upregulated in HBV-infected patients when compared to HC. Furthermore, the level of miRNAs in the CHB serum was upregulated most in hepatitis B e antigen-positive patients. The expression of MiR-122, the most abundant miRNA in liver tissue, was signi fi cantly higher in HBV infected groups than in HC. The expression of miR-223 was similar between HC and ASC, but increased signi fi cantly in CHB and ACLF. The expression levels of miR-122 and miR-194 correlated negatively with the age of patients with CHB or ACLF.

In an in vitro acute HCV infection model, 108 human miRNAs were identi fi ed whose expression levels changed for more than 2.0-fold in response to HCV infection [ 75 ] . Marquez et al. measured miR-122 and miR-21 levels in HCV-infected human liver biopsies relative to uninfected human livers and correlated these with clinical patient data [ 76 ] . They found that miR-21 expression correlated with viral load, fi brosis and serum liver transaminase levels. miR-122 expression inversely correlated with fi brosis, liver transaminase levels and patient age. While Morita et al. described hepatic miR-122 expression was weakly and positively correlated with the serum HCV load but was not correlated with HCV load in the human liver [ 77 ] .

Bihrer et al. found sera from patients with chronic HCV infection contained higher levels of miR-122 than sera from healthy controls [ 23 ] . Serum miR-122 levels correlated well with markers of liver in fl ammatory activity, that is, the serum levels of alanine leucine transaminase (ALT) and aspartate transaminase, and the histologic activity index (HAI) score. In patients with persistently normal ALT levels, serum miR-122 levels did not differ from healthy controls. There was no correlation of serum miR-122 levels with serum albumin, international normalized ratio, liver fi brosis, or serum HCV RNA. Thus, serum miR-122 appears to act as a biomarker of necroin fl ammation in patients with chronic Hepatitis C infection.

We previously performed a comprehensive miRNA pro fi ling in EV71-infected Hep2 cells using deep sequencing. A total of 64 miRNAs were found whose expression levels changed for more than twofold in response to EV71 infection [ 78 ] . Ho et al. found upregulation of miR-141 upon enterovirus infection can facilitate viral propagation by expediting the translational switch [ 79 ] . We recently compared host serum miRNA levels in patients with hand-foot-and-mouth disease caused by enterovirus 71 (EV71) and coxsackievirus 16 (CVA16) as well as in other microbial infections and in healthy individuals. Among 664 different miRNAs analyzed using a miRNA array, 102 were upregulated and 26 were downregulated in sera of patients with enteroviral infections. Expression levels of ten candidate miRNAs were further evaluated by quantitative real-time PCR assays. A receiver operating characteristic (ROC) curve analysis revealed that six miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis provided not only a sensitivity of 97.1 % and a speci fi city of 92.7 % but also a unique pro fi le that differentiated enteroviral infections from other microbial infections. Expression levels of fi ve miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and miR-140-5p) were signi fi cantly increased in patients with CVA16 versus those with EV71 ( p < 0.05). Combination of miR-545, miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of 0.761. These data indicate that sera from patients with different subtypes of enteroviral infection express unique miRNA pro fi les. Serum miRNA expression pro fi les may provide supplemental biomarkers for diagnosing and subtyping enteroviral hand-foot-and-mouth disease infections [ 80 ] .

Circulating miRNAs have been investigated as the diagnosis or prognosis marker for microbial infections. Studies on host miRNA pro fi les upon microbial infections are underway. There have a considerable way to go before being used in clinical practice. Several issues should be re fi ned in this fi eld. (a) Source material should be fi xed. Plasma, serum, whole blood, and isolated exosomes or microvesicles have been used as the source for miRNA pro fi ling. Advantages and disadvantages of each approach should be considered ahead. (b) Though differences in circulating miR-NAs between males and females have not been found with the exception of differences associated with pregnancy [ 81, 82 ] , miRNA levels in plasma and serum from a large number of normal individuals of both genders and various ages, even same individual over time should be extensively studied. (c) No acknowledged reference genes have been found in serum/plasma. Frequently used endogenous controls, such as miR-16, dysregulated in some diseases and RNU6B degraded in serum. Spiking into RNA isolation process with synthetic exogenous miRNA only act as normalizers for differences in recovery between samples. (d) The methods of miRNA quanti fi cation including RNA isolation should be standardized, since interplatform reproducibility among different platforms is low. (e) There seems to be a lack of speci fi city when using single miRNA as biomarker, since the miRNA is commonly regulated in various diseases. A panel of miRNAs should be a best choice.

Biomarkers for late-onset neonatal sepsis: cytokines and beyond

The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14

The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans

MicroRNAs and cancer: past, present, and potential future

MicroRNAs in cancer

MicroRNAs in organogenesis and disease

The roles of microRNAs in mammalian virus infection

Viral and cellular microRNAs as determinants of viral pathogenesis and immunity

Viruses, microRNAs, and host interactions

The microRNA spectrum in 12 body fl uids

Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma

Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases

Circulating microRNAs as stable blood-based markers for cancer detection

Microarray-based, high-throughput gene expression pro fi ling of microRNAs

MicroRNA: potential for cancer detection, diagnosis, and prognosis

Direct and sensitive miRNA pro fi ling from low-input total RNA

MicroRNA identi fi cation in plasma and serum: a new tool to diagnose and monitor diseases

Circulating microRNAs: association with disease and potential use as biomarkers

Identi fi cation of virus-encoded microRNAs

MicroRNA fi ngerprints identify miR-150 as a plasma prognostic marker in patients with sepsis

Serum miR-146a and miR-223 as potential new biomarkers for sepsis

Serum microRNA pro fi les serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma

Serum miR-122 as a biomarker of necroin fl ammation in patients with chronic hepatitis C virus infection

Human-and virus-encoded microRNAs as potential targets of antiviral therapy

Virus-encoded microRNAs

Modulation of hepatitis C virus RNA abundance by a liver-speci fi c MicroRNA

Cellular cofactors affecting hepatitis C virus infection and replication

Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes

MicroRNA pro fi le changes in human immunode fi ciency virus type 1 (HIV-1) seropositive individuals

Suppression of microRNA-silencing pathway by HIV-1 during virus replication

Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia

Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1

MicroRNome analysis unravels the molecular basis of SARS infection in bronchoalveolar stem cells

Identi fi cation of differentially expressed miR-NAs in chicken lung and trachea with avian in fl uenza virus infection by a deep sequencing approach

MicroRNA expression and virulence in pandemic in fl uenza virus-infected mice

High-throughput sequencing of microRNAs in adenovirus type 3 infected human laryngeal epithelial cells

Human cytomegalovirus infection alters the expression of cellular microRNA species that affect its replication

Combined agonist-antagonist genome-wide functional screening identi fi es broadly active antiviral microRNAs

HSV-1 infection of human brain cells induces miRNA-146a and Alzheimer-type in fl ammatory signaling

MiR-101 regulates HSV-1 replication by targeting ATP5B

regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator

The M type K15 protein of Kaposi's sarcoma-associated herpesvirus regulates microRNA expression via its SH2-binding motif to induce cell migration and invasion

Kaposi's sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 suppresses CXCR4 expression by upregulating miR-146a

Epstein-Barr virus-mediated dysregulation of human microRNA expression

microRNA pro fi ling in Epstein-Barr virus-associated B-cell lymphoma

Epstein-Barr virus growth/latency III program alters cellular microRNA expression

Induction of microRNA-155 during Helicobacter pylori infection and its negative regulatory role in the in fl ammatory response

MicroRNA signatures in Helicobacter pyloriinfected gastric mucosa

Dysfunctional gastric emptying with down-regulation of muscle-speci fi c microRNAs in Helicobacter pylori-infected mice

Analysis of the host microRNA response to Salmonella uncovers the control of major cytokines by the let-7 family

Integrated microRNA-mRNA-analysis of human monocyte derived macrophages upon Mycobacterium avium subsp. hominissuis infection

Regulation of cellular miRNA expression by human papillomaviruses

Expression pro fi ling of microRNA using real-time quantitative PCR, how to use it and what is available

Direct detection and quanti fi cation of microRNAs

Sensitive and speci fi c detection of microRNAs by northern blot analysis using LNA-modi fi ed oligonucleotide probes

Carbodiimide-mediated cross-linking of RNA to nylon membranes improves the detection of siRNA, miRNA and piRNA by northern blot

Role of miRNA in carcinogenesis and biomarker selection: a methodological view

Real-time quanti fi cation of microRNAs by stem-loop RT-PCR

MicroRNA expression pro fi ling of single whole embryonic stem cells

A microRNA array reveals extensive regulation of microRNAs during brain development

Microarray pro fi ling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes

A sensitive array for microRNA expression pro fi ling (miChip) based on locked nucleic acids (LNA)

A novel microarray approach reveals new tissuespeci fi c signatures of known and predicted mammalian microRNAs

An oligonucleotide microarray for microRNA expression analysis based on labeling RNA with quantum dot and nanogold probe

Assay: perfect match versus single-base mismatch. MicroRNA detection combining xMAP ® and locked nucleic acid (LNA™) technology

Next-generation DNA sequencing methods

The impact of next-generation sequencing on genomics

Systematic evaluation of three microRNA pro fi ling platforms: microarray, beads array, and quantitative real-time PCR array

Systematic comparison of microarray pro fi ling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression

NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses

MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells

In vivo pro fi le of the human leukocyte microRNA response to endotoxemia

Role of microRNAs in hepatitis B virus replication and pathogenesis

Circulating microRNAs in hepatitis B virus-infected patients

Systematic identi fi cation of microRNA and messenger RNA pro fi les in hepatitis C virus-infected human hepatoma cells

Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans

Clinical signi fi cance and potential of hepatic microRNA-122 expression in hepatitis C

Identi fi cation of microRNAs involved in the host response to enterovirus 71 infection by a deep sequencing approach

Enterovirus-induced miR-141 contributes to shutoff of host protein translation by targeting the translation initiation factor eIF4E

Serum microRNA expression pro fi le distinguishes enterovirus 71 and coxsackievirus 16 infections in patients with hand-foot-and-mouth disease

Detection and characterization of placental microR-NAs in maternal plasma

Serum microRNAs are promising novel biomarkers

The study was supported by the National Natural Science Foundation of China (30901285), the Jiangsu Province Key Medical Talent Foundation (RC2011191), the Science and Technology Pillar program of Jiangsu Province (BE2011796), and the "333" Projects of Jiangsu Province.